Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies entered into an R&D agreement for the use of ribozymes to treat and/or diagnose diseases associated with cancer, and cardiovascular,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury